Alignment Healthcare, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Goldman Sachs analyst Scott Fidel reduced Alignment Healthcare's (ALHC) price target to $12 from $25, citing elevated medical costs and future growth pressures. The firm maintains a Buy rating. This follows similar downgrades from UBS and TD Cowen.
Alignment Healthcare (ALHC) will add Astrana Health to its Medicare Advantage network in seven California counties from January 2027, expanding access to 3,000 PCPs and 6,500 specialists. This move supports ALHC's growth strategy in key markets.
Alignment Healthcare (ALHC) plans to expand its Medicare Advantage coverage to Bexar and Comal counties, including San Antonio, starting January 1, 2027, marking its second Texas market after El Paso. The move is part of a strategic expansion effort, with success contingent on enrollment, CMS ratings, and unit economics.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ALHC (Alignment Healthcare, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent ALHC coverage spans financial news, market movers and regulation.
In the last 30 days, ALHC insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($270K). The most active reporter was Kim Hyong, Chief Medical Officer, with 1 filing.
Target reduction suggests weaker outlook and may pressure the stock lower.
Network expansion may improve enrollment and revenue potential.
The new market entry could boost enrollment and revenue if CMS ratings hold, offering modest upside potential.
Alignment Healthcare could face continued selling pressure given its recent sharp decline and higher valuation multiple.
The expansion is likely to boost ALHC's growth outlook and support its recent 3.5% share price gain.
AlphAI scores every news story that mentions ALHC with an AI model for sentiment and relevance, and aggregates insider trades from Alignment Healthcare, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Goldman Sachs analyst Scott Fidel reduced Alignment Healthcare's (ALHC) price target to $12 from $25, citing elevated medical costs and future growth pressures. The firm maintains a Buy rating. This follows similar downgrades from UBS and TD Cowen.
1 min readAlignment Healthcare (ALHC) will add Astrana Health to its Medicare Advantage network in seven California counties from January 2027, expanding access to 3,000 PCPs and 6,500 specialists. This move supports ALHC's growth strategy in key markets.
1 min readAlignment Healthcare (ALHC) plans to expand its Medicare Advantage coverage to Bexar and Comal counties, including San Antonio, starting January 1, 2027, marking its second Texas market after El Paso. The move is part of a strategic expansion effort, with success contingent on enrollment, CMS ratings, and unit economics.
1 min readCVS Health (CVS) and Alignment Healthcare (ALHC) are major players in the growing Medicare Advantage market. CVS's Aetna segment saw improved margins and strong CMS ratings, while ALHC expanded membership and improved efficiency. CVS stock rose 9.9% over the past year, while ALHC fell 50.8%. CVS has a lower forward P/E (10.41) compared to ALHC (25.43), and its 2026 EPS estimates increased 1.8% in the past 60 days, unlike ALHC's 17.6% drop.
3 min readAlignment Health Plan, a unit of Alignment Healthcare Inc., will expand into four North Carolina counties starting January 1, adding 295,000 Medicare beneficiaries. This brings its total North Carolina coverage to 20 counties and 992,000 beneficiaries. The company's shares (ALHC) rose 3.5% to $8.37, giving it a market cap of $1.7 billion.
1 min readUBS maintained a neutral rating on Alignment Healthcare (ALHC) but lowered its price target from $22.00 to $9.00, citing market conditions. ALHC is trading at $8.09, which is 61.9% undervalued according to its GF Value™ of $21.22. The company has a GF Score™ of 62/100, with notable insider selling.
2 min readAlignment Healthcare (ALHC) shares rose 7% on Monday, recovering from a 13% drop the prior session. The previous decline followed the company's mixed CMS Star Ratings results. ALHC closed at $8.09, up 54 cents.
1 min readAlignment Healthcare sued CMS over its 2027 Medicare Advantage star ratings, alleging violations of the Administrative Procedure Act. The company claims the ratings were determined improperly, leading to financial and reputational damage. CMS recalculated scores after a similar lawsuit by Clover Health. Alignment seeks a court decision by May 2027.
6 min readAlignment Healthcare (ALHC) shares rose 8.6% after its subsidiary announced a new Medicare Advantage plan in Los Angeles and Orange counties. Analyst Ryan Langston lowered his price target to $12 but maintained a Buy rating, citing inpatient utilization pressure. The stock had fallen 13.4% the previous day due to a downgrade and regulatory concerns.
3 min readAlignment Health (ALHC) launches Central Health Harmony, a Medicare Advantage plan in Los Angeles and Orange counties starting Jan. 1, 2027. The plan offers access to 600+ Chinese-, Korean-, and Vietnamese-speaking doctors, culturally tailored benefits, and partnerships with Astrana Health and Hoag. The plan aims to improve healthcare access for seniors in multilingual communities.
3 min read
